Meeting
2011 ASCO Annual Meeting
Phase I study of regorafenib sequentially administered with either FOLFOX or FOLFIRI in patients with first-/second-line colorectal cancer.
Authors
B. Schultheis
Department of Hematology and Medical Oncology, University of Bochum (Marienhospital Herne), Herne, Germany
B. Schultheis , G. Folprecht , J. Kuhlmann , R. Ehrenberg , U. T. Hacker , C. Kohne , M. Kornacker , O. Boix , T. Lin , J. Krauss , R. Fischer , S. Hamann , D. Strumberg , K. B. Mross
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Clinical Trial Registration Number
NCT00934882
Citation
J Clin Oncol 29: 2011 (suppl; abstr 3585)
Abstract #
3585
Poster Bd #
16A
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
FORECAST-1: Feasibility of organoid response assessment to define effective treatments for patients with colorectal cancer after failure of standard therapy.
First Author: Margaret Lee
Poster
2015 Gastrointestinal Cancers Symposium
A phase II study of oxaliplatin reintroduction in patients pretreated with oxaliplatin and irinotecan for advanced colorectal cancer (RE-OPEN study).
First Author: Mitsukuni Suenaga
Poster
2014 ASCO Annual Meeting
A randomized phase III trial of mFOLFOX6 plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment for metastatic colorectal cancer: West Japan Oncology Group study 4407G (WJOG4407G).
First Author: Kentaro Yamazaki
Poster
2014 Gastrointestinal Cancers Symposium
Cost differential among systemic therapies for colon cancer.
First Author: Hasan Nadeem